Cell Therapy Technologies Market Is Expected To Grow At A CAGR Of 14.2% By 2033

According to a recently released Fact.MR analysis, the global market for cell treatment technologies is expected to generate sales of US$ 4.5 billion in 2022 and rise at a CAGR of 14.4% from 2023 to 2033. The market is anticipated to reach a US$ 19.6 billion worth by the end of 2033. The top three cell therapy technologies are media, sera, and reagents. From 2023 to 2033, the market for these items is anticipated to increase at a CAGR of 14.2%.

Technologies for cell therapy have evolved in terms of reliability, consistency, and safety. The primary driver of the market for cell treatment technologies is the rising prevalence of chronic diseases such multiple myeloma, solid tumours, lymphomas, leukaemia, and blood cancers. The evolution of new cell types, gene editing methods, and biomaterials, are the advanced cell therapy technologies used more frequently in both research and clinical settings.

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐚 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐓𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭:https://www.factmr.com/connectus/sample?flag=S&rep_id=8754?PJ

CAR-T cell therapy is a type of immunotherapy that involves modifying a patient's T cells to recognize and attack cancer cells. This therapy has shown promising results in the treatment of certain types of blood cancer, and several CAR-T cell therapies have been approved by regulatory agencies in the United States and Europe.

According to research, around 437 thousand new cases of leukemia were diagnosed worldwide and 309 thousand leukemia-related cancer deaths were reported in 2018. CAR T cell therapy was frequently used by the medical practitioner for the treatment of particular type of leukemia. Thus, it is anticipated that the market for cell therapy technologies will grow in the upcoming years.

In 2020, the Chinese government invested over US$ 15.5 billion in the biopharmaceutical industry, which includes cell therapy technologies. Due to increase in funding by the government, investors, and venture capitalists influence the growth of cell therapy technologies.

𝐂𝐨𝐮𝐧𝐭𝐫𝐲-𝐖𝐢𝐬𝐞 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬:

𝐔𝐧𝐢𝐭𝐞𝐝 𝐒𝐭𝐚𝐭𝐞𝐬 𝐂𝐞𝐥𝐥 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐢𝐞𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐒𝐭𝐮𝐝𝐲 :

The market in the United States is anticipated to increase by US$ 3.3 billion in absolute terms from 2023 to 2033, reaching a value of US$ 4.4 billion. From 2018 to 2022, the market in the United States grew at a CAGR of 11.7%, and from 2023 to 2033, it is anticipated to grow at a CAGR of 14.2%.

Also, the American Food and Drug Administration (FDA) has taken action to promote the creation of cell therapy treatments. The FDA introduced its Regenerative Medicine Advanced Treatment (RMAT) designation programme in 2017, which offers regenerative medicine products-including cell therapy-advanced technology and review. In order to advance the development of cell therapy, the government has launched a number of programmes and offers

𝐂𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐢𝐯𝐞 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬:

𝐊𝐞𝐲 𝐩𝐥𝐚𝐲𝐞𝐫𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐦𝐚𝐫𝐤𝐞𝐭 𝐚𝐫𝐞:-

• Thermo Fischer Scientific, Inc.,
• Merck KGaA,
• Danaher Corporation,
• Lonza Group,
• Sartorius,
• Terumo BCT,
• Becton Dickinson and Company,
• Fresenius SE & Co. KGaA,
• Avantor Inc.,
• Bio-Techne Corporation,
• Corning Incorporated,
• FUJIFILM Irvine Scientific,
• MaxCyte Inc.,
• RoosterBio Inc.

𝐀 𝐟𝐞𝐰 𝐨𝐟 𝐭𝐡𝐞 𝐫𝐞𝐜𝐞𝐧𝐭 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐜𝐞𝐥𝐥 𝐭𝐡𝐞𝐫𝐚𝐩𝐲 𝐭𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐢𝐞𝐬 𝐦𝐚𝐫𝐤𝐞𝐭 𝐚𝐫𝐞:

• 𝐈𝐧 𝐉𝐮𝐧𝐞 𝟐𝟎𝟐𝟐, Bio-Techne Corporation, a global provider of innovative tools and bioactive reagents for the research and clinical diagnostic acquired Namocell, a leading provider of fast and easy to use single cell sorting and dispensing platforms that are gentle to cells, and preserve cell viability and integrity.

• 𝐈𝐧 𝐅𝐞𝐛𝐫𝐮𝐚𝐫𝐲 𝟐𝟎𝟐𝟎, Immatics Biotechnologies GmbH collaborates with GSK, for the identification, research and development of next-generation T-Cell Receptor (TCR) Therapeutics with a focus on solid tumors.

𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐭𝐡𝐞 𝐂𝐞𝐥𝐥 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐢𝐞𝐬 𝐌𝐚𝐫𝐤𝐞𝐭:

• 𝐁𝐲 𝐏𝐫𝐨𝐝𝐮𝐜𝐭:
• Media, Sera, and Reagents
• Cell Engineering Products
• Cell Culture Vessels
• Cell Therapy Equipment
• Cell Processing Equipment
• Single-use Equipment
• Systems and Software

• 𝐁𝐲 𝐏𝐫𝐨𝐜𝐞𝐬𝐬:
• Cell Processing
• Cell Preservation, Distribution, and Handling
• Process Monitoring and Quality Control

• 𝐁𝐲 𝐂𝐞𝐥𝐥 𝐓𝐲𝐩𝐞:
• T-cells
• Stem Cells
• Other Cells

• 𝐁𝐲 𝐄𝐧𝐝 𝐔𝐬𝐞𝐫:
• Biopharmaceutical & Biotechnology Companies
• CROs and CMOs
• Research Institutes and Cell Banks

• 𝐁𝐲 𝐑𝐞𝐠𝐢𝐨𝐧:
• North America
• Latin America
• Europe
• Asia Pacific
• Middle East & Africa

𝐌𝐨𝐫𝐞 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐀𝐯𝐚𝐢𝐥𝐚𝐛𝐥𝐞

Fact.MR, in its new offering, presents an unbiased analysis of the cell therapy technologies market, presenting historical market data (2018-2022) and forecast statistics for the period from 2023 to 2033.

The study reveals extensive growth in Cell Therapy Technologies Market by Product (Media, Sera, and Reagents, Cell Engineering Products, Cell Culture Vessels, Cell Therapy Equipment, Cell Processing Equipment, Single-use Equipment, Systems and Software), by Process (Cell Processing, Cell Preservation, Distribution, and Handling, Process Monitoring and Quality Control), by Cell Type (T-cells, Stem Cells, Other Cells), by End User (Biopharmaceutical & Biotechnology Companies, CROs and CMOs, Research Institutes and Cell Banks), and by Region (North America, Latin America, Europe, Asia- Pacific , Middle East and Africa) from 2023 to 2033

𝐆𝐞𝐭 𝐂𝐮𝐬𝐭𝐨𝐦𝐢𝐳𝐚𝐭𝐢𝐨𝐧 𝐨𝐧 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐟𝐨𝐫 𝐒𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐒𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐬:https://www.factmr.com/connectus/sample?flag=RC&rep_id=8754?PJ

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E Mail : sales@factmr.com

About Fact.MR

Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. Spanning a wide range - from automotive & industry 4.0 to healthcare, technology, chemical and materials, to even the most niche categories.

This release was published on openPR.